Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Extensive Stage Lung Small Cell Carcinoma 1

Interventions

Cytarabine 167fludarabine phosphate 102Cyclophosphamide 97Azacitidine 92Whole-Body Irradiation 78fludarabine 77Mycophenolic Acid 71Busulfan 68Tacrolimus 59Peripheral Blood Stem Cell Transplantation 55Decitabine 55Granulocyte Colony-Stimulating Factor 49Filgrastim 44Daunorubicin 44Cyclosporine 42Methotrexate 41Melphalan 41Etoposide 41Clofarabine 41Idarubicin 39Mitoxantrone 34Antilymphocyte Serum 34venetoclax 32thymoglobulin 23Thiotepa 23Stem Cell Transplantation 21Injections 16Gemtuzumab 16CPX-351 16Sirolimus 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid, Acute × bomedemstat × Clear all
NCT02842827 2023-07-11

IMG-7289-CTP-101

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 1/2 Completed
45 enrolled 41 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡